Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 15/20 | 0.70 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.70 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.70 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908282 | 0.91 | OXTR (0.65) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL9908280 | 0.89 | OXTR (0.72) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL15511771 | 0.86 | OXTR (0.77) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL16790726 | 0.85 | OXTR (0.86) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL15512016 | 0.84 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL29355099 | 0.84 | OXTR (0.72) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL15511602 | 0.84 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL16373316 | 0.83 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL29048 | 0.83 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL20707334 | 0.83 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | OXTR 2886/4885AVPR1A 2676/4885AVPR2 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.